Insight

Intratumoral immune triads are required for effective immunotherapy

Photo taken from NCI/LinkedIn

Jun 26, 2024, 02:10

Intratumoral immune triads are required for effective immunotherapy

NCI Division of Cancer Biology shared on X:

“Using preclinical models in an NCI-funded study, Gabriel Espinosa Carrasco, The SchietiLab, et al. found that intratumoral immune triads (with a dendritic cell, CD4 T cell, and CD8 T cell) are required for effective immunotherapy.”

immunotherapy

Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors

Authors: Gabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, Paul Zumbo, Asim Dave, Doron Betel, Sung Wook Kang, Hee-Jin Jang, Matthew D. Hellmann, Bryan M. Burt, Hyun-Sung Lee, Andrea Schietinger

Source: NCI Division of Cancer Biology/X

Andrea Schietinger Asim Dave Aurora Scrivo Bryan M. Burt cancer Doron Betel Edison Chiu Gabriel Espinosa Carrasco Hee-Jin Jang Hyun-Sung Lee immunotherapy Matthew D. Hellmann NCI Division of Cancer Biology OncoDaily Oncology Paul Zumbo Sung Wook Kang The SchietiLab

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer